Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 fatty acids for ADHD and DESR in adults
NCT01399827Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2012
- Primary completion
- Nov 2017
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omega-3 fatty acid in attention deficit hyperactivity disorder (ADHD), sponsored by Massachusetts General Hospital. Started Feb 2012; status: completed.
02
Drugs
omega-3 fatty acid
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01399827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01399827.